Kura Oncology (KURA) – Research Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Kura Oncology (NASDAQ: KURA) in the last few weeks:

• 11/22/2024 – Kura Oncology had its price target lowered by analysts at Bank of America Co. from $36.00 to $29.00. They now have a “buy” rating on the stock.
• 11/21/2024 – Kura Oncology had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/21/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at TD Cowen.
• 11/21/2024 – Kura Oncology had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a “buy” rating on the stock.
• 11/21/2024 – Kura Oncology had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a “buy” rating on the stock.
• 11/20/2024 – Kura Oncology was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/19/2024 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
• 11/13/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 11/12/2024 – Kura Oncology was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/6/2024 – Kura Oncology had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/6/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 11/4/2024 – Kura Oncology had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
• 10/24/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 10/24/2024 – Kura Oncology is now covered by analysts at UBS Group AG. They set a “buy” rating and a $27.00 price target on the stock.
• 10/22/2024 – Kura Oncology was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
• 10/14/2024 – Kura Oncology was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $19.00 price target on the stock, down previously from $26.00.

Kura Oncology Price Performance

KURA opened at $10.75 on Wednesday. The stock has a fifty day moving average price of $17.68 and a 200 day moving average price of $19.60. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 1 year low of $9.06 and a 1 year high of $24.17. The stock has a market cap of $835.92 million, a price-to-earnings ratio of -4.56 and a beta of 0.86.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Kura Oncology by 17.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after buying an additional 2,940 shares in the last quarter. Artal Group S.A. raised its position in shares of Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Kura Oncology by 25.6% during the second quarter. Harbor Capital Advisors Inc. now owns 38,790 shares of the company’s stock valued at $799,000 after acquiring an additional 7,899 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares during the period.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.